RxDoctor Payments DataLook up a doctor →

Don Stevens, MD

Medical Oncology · Louisville, KYNPI 1952369621

Payments from drug & device makers

$15,997,922in general payments, 2019–2025

Across 2,108 payments — averaging $7589.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$2.4M
  • Beigene, Ltd.$2M
  • AbbVie$1.9M
  • Regeneron$1.4M
  • Bristol Myers Squibb$1.4M
  • Acerta Pharma LLC$1.3M
  • plus $5.8M from 39 others
$396,773in research payments, 2019–2025

Across 38 payments — averaging $10,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ichnos Glenmark Innovation Inc$349K
  • Acrotech Biopharma Inc.$37K
  • Regeneron$6K
  • Pfizer$2K
  • Bristol Myers Squibb$1K
  • F. Hoffmann-la Roche AG$1K

What the payments were for

  • Consulting fees$11,15070%
  • Speaking & faculty fees$3362%
  • Travel & lodging$1,2378%
  • Food & beverage$2,79318%
  • Education$3492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,997,922 in reported general payments places this provider in the 95th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$205,076
Medicare patients
512
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib123$1,694,580
VenclextaVenetoclax109$893,118
ImbruvicaIbrutinib31$735,196
RevlimidLenalidomide37$557,860
PomalystPomalidomide22$428,142
VonjoPacritinib Citrate17$376,775
JakafiRuxolitinib Phosphate21$351,330
OnuregAzacitidine15$305,592
CalquenceAcalabrutinib Maleate23$289,253
SprycelDasatinib17$280,751
XareltoRivaroxaban28$34,066
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$32,433
EliquisApixaban34$29,390
Xtampza ErOxycodone Myristate13$26,189
OxycontinOxycodone Hcl11$20,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$74,249$1,694,580123 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg, Sprycel$543,255$1,014,48454 claims
AbbVieVenclexta$1,879,325$893,118109 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$454,403$735,19631 claims
Bristol Myers SquibbRevlimid$1,359,230$557,86037 claims
Incyte CorporationJakafi$159,650$351,33021 claims
AstraZenecaCalquence$356,649$289,25323 claims
Johnson & JohnsonXarelto$202$34,06628 claims
PfizerEliquis$844,681$29,39034 claims
Lilly USA, LLCOlanzapine$92$35117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 medical oncology providers in Kentucky.

Other medical oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →